Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Maximum Tolerated Dose × Gynecologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 2 Gynecologic 1 Genitourinary 1 Gastrointestinal 1

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 236 Carboplatin 236 Cisplatin 169 Bevacizumab 120 pembrolizumab 87 Surveys and Questionnaires 71 Cyclophosphamide 70 Radiotherapy 67 olaparib 59 Blood Specimen Collection 56 Hyperthermic Intraperitoneal Chemotherapy 54 Gemcitabine 53 Drug Therapy 51 Topotecan 50 niraparib 49 Brachytherapy 47 liposomal doxorubicin 44 Docetaxel 43 Taxes 40 Magnetic Resonance Spectroscopy 40 Letrozole 32 Cytoreduction Surgical Procedures 31 Biopsy 31 Surgical Procedures, Operative 29 Doxorubicin 29 durvalumab 28 Specimen Handling 28 Filgrastim 28 Nivolumab 27 fludarabine 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06976892 2025-08-13

IDOL

Institute of Cancer Research, United Kingdom

Phase 1 Recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡